BD
BDMD.US Baird Medical Investment Holdings Limited
- Market cap
- USD 2.91M
- P/E
- -
- P/B
- 0.10x
- ROE
- -91.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BDMD.US undervalued?
Graham numberThe Graham number of Baird Medical Investment Holdings Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Baird Medical Investment Holdings Limited fundamental analysis
No fundamental analysis for Baird Medical Investment Holdings Limited yet.
Baird Medical Investment Holdings Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Baird Medical Investment Holdings Limited
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as s…
Full company profileBaird Medical Investment Holdings Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Baird Medical Investment Holdings Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 12.2M | 18.1M | 27.7M | 35.1M | 31.5M | 37.0M | 22.5M | 49.0M |
| Gross Profit | 10.9M | 15.6M | 23.2M | 28.0M | 27.2M | 32.7M | 18.9M | 41.9M |
| Operating Income | 5.61M | 9.86M | 11.9M | 13.6M | 11.9M | 15.3M | -25.5M | -28.7M |
| EBITDA | 6.13M | 10.7M | 14.2M | 16.3M | 13.2M | 16.2M | -24.5M | -26.0M |
| Net Income | -7.18M | 7.10M | 11.7M | 12.6M | 10.5M | 12.5M | -27.3M | -31.9M |
| EPS | -1.00 | 0.99 | 1.62 | 1.75 | 1.39 | 0.49 | -0.98 | -0.78 |
| Balance Sheet | ||||||||
| Total Assets | 11.8M | 17.0M | 26.1M | 42.6M | 56.7M | 78.0M | 69.7M | 73.8M |
| Total Liabilities | 34.3M | 10.3M | 10.3M | 16.8M | 21.0M | 38.2M | 38.5M | 39.2M |
| Shareholders' Equity | -21.9M | 7.21M | 5.20M | 25.9M | 35.8M | 39.7M | 31.4M | 34.8M |
| Cash & Short-term Investments | 257K | 1.14M | 3.44M | 1.91M | 1.63M | 2.97M | 178K | 289K |
| Total Debt | 28.9M | 4.05M | 2.93M | 7.44M | 9.90M | 20.9M | 19.3M | 14.2M |
| Cash Flow | ||||||||
| Operating Cash Flow | 4.41M | 3.91M | 5.26M | 486K | -1.02M | -6.31M | -1.34M | 8.61M |
| Capital Expenditure | 984K | 655K | 1.39M | 5.95M | 2.64M | 2.85M | 42.3K | 4.59K |
| Free Cash Flow | 3.43M | 3.25M | 3.87M | -5.47M | -3.66M | -9.17M | -1.39M | 8.61M |
| Ratios | ||||||||
| ROE | - | 98.4% | 224.4% | 48.5% | 29.5% | 31.4% | -87.0% | -91.7% |
| ROA | -61.1% | 41.7% | 44.7% | 29.5% | 18.6% | 16.0% | -39.1% | -43.2% |
| Net Profit Margin | -58.8% | 39.2% | 42.1% | 35.8% | 33.5% | 33.6% | -121.0% | -65.1% |
| Debt to Equity | - | 0.56x | 0.56x | 0.29x | 0.28x | 0.53x | 0.62x | 0.41x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Baird Medical Investment Holdings Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 5.43M | 0.75 | 46.5% |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Baird Medical Investment Holdings Limited
- Insiders 86.49%
- Institutions 1.06%
- Public & others 12.45%
- Shares outstanding 32.1M
- Free float 6.50M
Top funds holding BDMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 19.6K | 0.06% | 0.00% | Aug 2026 |
Top institutions holding BDMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| UBS Group AG | 58.7K | 0.18% | -13.52% | Jun 2026 |
| Two Sigma Investments LLC | 55.5K | 0.17% | +19.13% | Jun 2026 |
| Renaissance Technologies Corp | 55.4K | 0.17% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 54.9K | 0.17% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 31.6K | 0.10% | -19.90% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 28.5K | 0.09% | +143.45% | Jun 2026 |
| Geode Capital Management, LLC | 19.6K | 0.06% | -22.98% | Jun 2026 |
| XTX Topco Ltd | 11.2K | 0.03% | 0.00% | Jun 2026 |
| Wolverine Asset Management LLC | 205.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 4.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Highbridge Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Baird Medical Investment Holdings Limited company profile
- Company name
- Baird Medical Investment Holdings Limited
- Ticker
- BDMD.US
- ISIN
- KYG0705H1039
- Exchange
- USA Stocks
- Listed since
- Oct 1, 2024
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 146
- Fiscal year end
- December
- Address
- Baide Building, Building 11, Guangzhou, China
- Phone
- 86 20 8218 5926
- Website
- bairdmed.com
About Baird Medical Investment Holdings Limited
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation. It sells its products through third-party distributors. It has a strategic cooperation agreement with Tianjin Yuanshan Medical Technology Co., Ltd. to focus on global development and commercialization of next-generation IRE technologies. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.
Baird Medical Investment Holdings Limited management
6- Ms. Haimei WuChairwoman of the Board of Directors & CEO · born 1982
- Ms. Quan QiuChief Administrative Officer & Executive Director · born 1993
- Mr. Wei HouExecutive Director · born 1970
- Ms. Jie LiActing Chief Financial Officer · born 1988
- Mr. Rongjian LuCTO & Deputy GM · born 1967
- Mr. Mark S. SaxtonChief Executive Officer U.S. Subsidiary · born 1965